Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

J Hepatocell Carcinoma · 2017 · PMC5396941 · PMID 28443252

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

highly significantP =0.006actually significant

Wilcoxon signed rank test used as non-parametric counterpart to the parametric paired t -test has revealed highly significant difference ( P =0.006).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.